Value through Innovation27 July 2016

Clinical Study Results

  • FLOMAX ® - Lower Urinary Tract Symptoms
    Clinical Study Number 527.25
    Study Indication Lower Urinary Tract Symptoms
    Product FLOMAX ®
    Generic Name Tamsulosin
    Lab Code
    Clinical Phase II
    Study Title

    An eight-week, double-blind, randomized, parallel group design, multicenter study of FLOMAX® capsules, 0.4 mg daily versus placebo, in female patients with lower urinary tract symptoms (LUTS) with a significant component of voiding symptoms

    Study Document Trial synopsis 527.25 english
  • FLOMAX ® - Lower Urinary Tract Symptoms
    Clinical Study Number 527.30
    Study Indication Lower Urinary Tract Symptoms
    Product FLOMAX ®
    Generic Name Tamsulosin
    Lab Code
    Clinical Phase IV
    Study Title

    BLADDER (BPH, LUTS And Detrusor: Dual Effect Research) study: A multicentre, double-blind, randomised, parallel group, placebo-controlled study, aimed at characterising the effect of tamsulosin on Lower Urinary Tract Symptoms (LUTS) and detrusor motor activity in patients affected by benign prostatic hyperplasia (BPH) and storage urinary symptoms.

    Study Document Trial synopsis 527.30_CO english
  • FLOMAX ® - Lower Urinary Tract Symptoms
    Clinical Study Number 527.68
    Study Indication Lower Urinary Tract Symptoms
    Product FLOMAX ®
    Generic Name Tamsulosin
    Lab Code
    Clinical Phase IV
    Study Title

    The Impact of Alna® Ocas® on Nocturia in patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

    Study Document Trial synosis 527.68 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.